Chhindwara:Tragedy struck Chhindwara again after a five-month-old baby girl died allegedly after consuming an Ayurvedic cough syrup and a medicinal powder, officials said on Friday. The incident comes barely two weeks after a series of child deaths linked to a toxic cough syrup 'Coldrif'. The latest death has taken the toll from the use of liquid formulations to 25. "Ruhi Minote, who was suffering from cold and cough, died on Thursday. Her family had purchased an Ayurvedic syrup and some medicinal powder from Kuratha Medical Shop four days earlier. The medical shop has been sealed," Chaurai Sub-Divisional Magistrate (SDM) Prabhat Mishra told PTI. "A case of unnatural death has been registered by police. Samples of the syrup and powder have been sent for testing. The viscera has been sent to the forensic science laboratory (FSL) in Jabalpur. We are waiting for the post-mortem report," the SDM added. Earlier, 24 children, comprising 21 from Chhindwara, two from Betul and one from Pandhurna, died of renal failure linked to consumption of 'Coldrif', an allopathiccough syrupfound to contain 48.6 per cent diethylene glycol, a highly poisonous compound.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!